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ABSTRACT
Despite extensive efforts, cancer therapies directed at the Protein Kinase C (PKC) 
family of serine/threonine kinases have failed in clinical trials. These therapies have 
been directed at inhibiting PKC and have, in some cases, worsened disease outcome. 
Here we examine colon cancer patients and show not only that PKC Beta II is a 
tumour suppressor, but patients with low levels of this isozyme have significantly 
decreased disease free survival. Specifically, analysis of gene expression levels of all 
PKC genes in matched normal and cancer tissue samples from colon cancer patients 
revealed a striking down-regulation of the gene coding PKC Beta in the cancer tissue 
(n = 21). Tissue microarray analysis revealed a dramatic down-regulation of PKC 
Beta II protein levels in both the epithelial and stromal diseased tissue (n = 166). 
Of clinical significance, low levels of the protein in the normal tissue of patients is 
associated with a low (10%) 10 year survival compared with a much higher (60%) 
survival in patients with relatively high levels of the protein. Consistent with PKC 
Beta II levels protecting against colon cancer, overexpression of PKC Beta II in colon 
cancer cell lines reveals that PKC Beta II reverses transformation in cell based assays. 
Further to this, activation of PKC Beta II results in a dramatic downregulation of IGF-
I-induced AKT, indicating a role for PKCs in regulating IGF-1 mediated cell survival. 
Thus, PKC Beta II is a tumour suppressor in colon cancer and low levels serve as a 
predictor for poor survival outcome. 
INTRODUCTION 
Following the discovery that the Protein Kinase C 
(PKC) family members were high affinity intracellular 
receptors for phorbol-ester tumour promotors, the serine/
threonine kinases were studied intensively in the context 
of targeting them in cancer [1–5]. Yet their precise role in 
cancer has remained elusive.
PKC is a family of serine/threonine kinases 
whose 9 members are expressed in many different 
tissue types and have diverse biological functions. The 
PKC isozymes are responsible for mediating several 
biological processes including cell-cycle regulation, cell 
survival, cell adhesion and the regulation of apoptosis 
[6, 7]. All members of the PKC family share common 
basic structures; a flexible hinge segment linking a cell 
membrane targeting N-terminal regulatory moiety to a 
C-terminal catalytic domain [8, 9]. The regulatory moiety 
contains two discrete membrane targeting modules and 
a pseudosubstrate segment that maintain the enzyme 
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in an inactive conformation [9, 10]. The maturation of 
PKCs into this autoinhibited conformation is dependent 
on sequential phosphorylation steps at three highly 
conserved sites termed the activation loop, the turn 
motif, and the hydrophobic motif [11–13]. Following 
these phosphorylation events, the protein is activated by 
specific secondary messengers that bind to the regulatory 
domain to mediate the release of the pseudosubstrate 
segment from the active site [10, 14]. The classical PKCs 
are targeted by diaclyglycerol (DAG) and Ca2+, the novel 
PKCs are activated by DAG alone, and the atypical PKCs 
bind neither DAG nor Ca2+, instead are regulated by 
protein:protein interactions [6, 15]. Prolonged activation 
of PKCs with phorbol esters results in a downregulation of 
the protein as a result of dephosphorylation and subsequent 
degradation [16–18]. 
Research into the role of different PKC isoforms in 
cancer is based primarily on the assumption that increased 
PKC activation and expression promotes carcinogen 
induced tumorigenesis [1–3, 19, 20]. A large body of 
evidence supports this, for example, overexpression of 
PKCε is a suggested tumour promoter in stomach, lung, 
thyroid, colon and breast cancer [4], increased levels of 
PKCη are associated with tumour aggressiveness and 
an increased rate of cell proliferation in non-small-cell 
lung cancer [21] and overexpression of PKC θ is linked 
to gastrointestinal stromal tumours [22]. However, 
immunohistochemical and biochemical studies indicate 
that altered expression of the PKC isoforms is variable 
and depends on the cancer type [5, 23, 24]. For example, 
it has been shown that PKCα can both induce and supress 
colon cancer cell proliferation [25, 26]. Similarly, PKCζ 
overexpression in colon cancer cell lines decreases 
tumour formation in nude mice while loss of PKCζ is also 
associated with decreased tumorigenicity [27, 28]. The 
expression of PKCβ in breast, gastric and colon cancer has 
been subject to much debate and there are many studies 
presenting arguments for both up and down regulation of 
the isoform in cancer cells and cancer tissue [29–34]. 
Collectively, this research has driven the 
development of several target therapies against cancer 
[5, 34, 35]. These targeted therapies are showing promise 
as potential drugs in the treatment of cardiac diseases 
[36–40] and bipolar mania [41–43], suggesting that there 
is merit in targeting PKC [5]. However, PKC inhibitors 
have proved unsuccessful as anti-cancer agents in clinical 
trials [5, 44]. Further to this, meta-analysis conducted on 
controlled clinical trials of chemotherapy alone versus 
chemotherapy combined with PKC inhibitors discovered 
response rates and disease control rates were significantly 
reduced in the groups that were administrated PKC 
inhibitors [45]. Taken together, this challenges the view 
that PKCs are acting as tumour promotors and strongly 
suggests that a recalibration of our understanding of 
how PKC’s function in cancer may be required. In fact, 
recent work examining PKC mutations in human cancers 
revealed that approximately 60% of PKC mutations 
actually reduced or abolished PKC activity and none were 
activating, proposing that PKCs could be playing a tumour 
suppressor role [46]. This study also demonstrated that 
correction of one loss of function PKC Beta II mutation in 
a colon cancer cell line actually decreased tumour size in 
mouse xenografts [46]. 
In our investigation, we set out to compare the 
expression of all the PKC isoforms in colorectal cancer 
to understand whether its function was enhanced or 
reduced in this cancer. Keeping in mind that PKCs are 
differentially expressed across and within different tissues, 
our approach was to reduce any variability that may occur 
between patients by examining the expression of the genes 
encoding PKCs in patients matched normal and colorectal 
cancer tissue. Our analysis revealed a dysregulation of 
many of the isoforms with a striking down regulation of 
the PKC Beta II isoform in the cancer tissue. To further 
investigate the implication of this in colorectal cancer, we 
examined the protein expression of PKC Beta II across 
a large cohort of patients and compared expression of 
PKC Beta II in normal distant tissue, normal adjacent 
tissue, cancer tissue and tumour edge tissue. Interestingly, 
this revealed a dramatic downregulation of the protein 
in the cancer and tumour edge tissue. Further to this, 
we found a strong association between low levels of 
PKC Beta II in normal distant tissue and a reduction in 
disease free survival time for colorectal cancer (CRC) 
patients. To substantiate our findings, we overexpressed 
PKC Beta II in colon cancer cells and used a series of 
cell based assays including real-time cell migration 
and cell invasion assays to reveal that overexpression of 
PKC Beta II reverses the transformed phenotype. Upon 
further investigation we revealed that both activation 
and overexpression of PKC Beta II dramatically reduced 
phosphorylation of AKT and consequently reduced cell 
survival. All these data combined strongly suggest that 
PKC Beta II has a tumour suppressor role in colon cancer. 
RESULTS
The genes encoding protein kinase C isoforms 
are dysregulated in colon cancer
To investigate the change in PKC expression in 
colon cancer, we used fresh tissue samples that were 
excised from both the cancer tissue and normal distant 
tissue of individual patients. Using real time PCR, we 
compared PKC expression in their normal distant tissue 
to their cancer tissue and established an individual fold 
change for each patient. After averaging the fold change of 
all patients for each PKC coding gene, PRKCB, PRKCD 
and PRKCE demonstrated a down-regulation greater than 
two while PRKCG was upregulated (Figure 1A, S1). This 
suggests that there is differential expression of the genes 
encoding PKC when the cancer tissue and normal tissue of 
individuals are compared. The most striking dysregulation 
was the downregulation of the gene coding for the protein 
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PKC Beta II. This dysregulation was not influenced by 
the progression of the disease as no statistical difference 
was found between stage 2 and stage 3 patients 
(Supplementary 2A). To investigate this further we 
examined the relative expression of PRKCB in normal 
distant tissue and compared it to cancer tissue, normal 
tissue and benign tissue (Figure 1B, S2B). We found a 
significant downregulation of PRKCB in the cancer tissue 
compared to the normal distant tissue (p < 0.01), with no 
difference between the other tissue groups examined. 
PKC Beta II is down-regulated in tumours from 
CRC patients
The changes we observed in the expression of 
PKC Beta II are noteworthy as there are some conflicting 
results in the literature. Earlier studies suggested that 
PKC Beta II expression is upregulated and is an early 
event in colon cancer in mice [32]. This considered we 
next wanted to determine if this downregulation was 
observed at a protein level in CRC patients. To do this, 
we examined the expression of mature PKC Beta II in 197 
CRC tissue samples (Table 1), using tissue microarrays 
and immunohistochemistry. As expected, and in support 
of our gene analysis, expression of PKC Beta II was 
significantly reduced in the cancer epithelium tissue 
when compared with normal distant epithelium tissue 
(p < 0.01) (Figure 2A, 2B). Similar results were found 
when comparing cancer stromal tissue with normal distant 
stromal tissue (p < 0.01) (Figure 2A, 2B). 
In addition, we examined the expression of mature 
PKC Beta II in tumour cores representative of normal 
adjacent and tumour edge tissue. Again, expression was 
significantly reduced in the tumour edge epithelium tissue 
(p < 0.01) when compared with normal distant epithelium 
and normal adjacent epithelium tissue, while no 
significant difference was observed between tumour edge 
epithelium and cancer epithelium tissue (Figure 2A, 2B). 
Similar results were also obtained for the stromal tissue 
(Figure 2A, 2B). Comparable to our gene expression 
analysis, progression of the disease did not influence the 
protein levels of PKC Beta II (Supplementary 3). To the 
best of our knowledge, our data show for the first time 
that PKC Beta II is down-regulated at both the gene and 
protein level in CRC tissue.
Low expression of PKC Beta II in normal distant 
epithelium tissue is associated with a reduction 
in disease free survival time
To test whether a low expression of PKC Beta II was 
associated with a poor prognosis we compared the survival 
of patients with low and high expression of PKC Beta II. 
Low and high expression values were determined using 
histograms; with values less than the median designated 
low expression, and those greater than the median 
designated high expression (Supplementary 4A, 4B). 
Remarkably, although fewer patients had low 
expression of PKC Beta II in their normal distant tissue 
(Supplementary 4C, 4D), those patients that did have low 
expression in their normal distant epithelium tissue showed 
a significant reduction in their disease free survival time 
(p < 0.01) (Figure 3A). Interestingly, this was only true 
for the normal distant epithelium tissue as no significant 
difference was observed between high and low expression 
in the normal distant stromal tissue (Figure 3B). Moreover, 
there was no reduction in the disease free survival time 
associated with low and high expression in either the 
cancer epithelial tissue (Figure 3C) or the cancer stromal 
tissue (Figure 3D). This reflects our findings that the 
downregulation of PKC Beta II is not progressive across 
tumour stage (Figure S2A and S3). Consequently, as 
expected, lower expression in the cancer epithelium is not 
associated with a reduction in disease free survival. 
Overexpression of PKC Beta II reverses the 
transformed phenotype of HCT116 cells
Our data indicate that there is a downregulation of 
PKC Beta II in colorectal cancer. Given this observation 
we predict that overexpressing PKC Beta II in colon 
cancer cells would reverse the transformed phenotype. 
To test this, we generated HCT116 cells overexpressing 
PKC Beta II (Figure 4A) and carried out a number of 
cell based assays. Using a colony formation assays, we 
observed that cells overexpressing PKC Beta II show 
a significant reduction in the ability to form colonies 
(p < 0.05) (Figure 4B). Next, we wanted to examine if 
cells overexpressing PKC Beta II would show altered 
behaviour in 3-Dimensional culture. Strikingly, 3D 
cultures overexpressing PKC Beta II showed a 50% 
reduction in culture size after 144 hours (Figure 4C, 
S5A). In an attempt to get a more comprehensive 
view of the phenotype of the 3D cultures, they were 
extracted at 144 hours, fixed, stained and observed using 
confocal microscopy. Cultures expressing empty vector 
demonstrated a migratory phenotype, reminiscent of wild 
type HCT116 cultures, however, in cells overexpressing 
PKC Beta II, the cultures were more organised and 
remained small and rounded (Figure 4C). 
Next, we tested whether PKC Beta II overexpression 
would have an influence on the migratory capacity 
of HCT116 cells. To do this, we carried out a wound 
migration assay using ibidi® inserts and observed a 
significant reduction in the ability of cells overexpressing 
PKC Beta II to migrate into the wound (p < 0.01) 
(Figure 4D). Our observations are due to the decreased 
migratory behaviour of the overexpressing cells as no 
difference was observed in the rate of proliferation 
(Supplementary 5B). Following this, we wanted to monitor 
the migratory behaviour of the cells in real time using 
the xCELLigence CIM-plates configuration. Serum starved 
overexpressing cells were placed in the upper chamber of 
the CIM-plates with 10% FBS acting as a chemoattractant 
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in the lower chamber. Strikingly, cells overexpressing 
PKC Beta II showed an 80% reduction in the ability 
to migrate towards the chemoattractant after 72 hours 
(p < 0.01) (Figure 4E). To test if the invasive property 
of HCT116 cells was altered in the overexpressing cells, 
a similar assay was set up, with an additional matrigel 
layer added to the upper chamber of the CIM-plates to 
stimulate the ECM and to provide a barrier for the cells to 
invade [47]. As above, cells overexpressing PKC Beta II 
demonstrated a significant reduction in the rate of invasion 
towards the chemoattractant (p < 0.01) (Figure 4F). All 
this information considered would indicate that PKC Beta 
Figure 1: Gene expression of PKC genes in colon cancer. Tissue samples measuring approximately 0.5 cm in diameter were 
collected from 21 patients undergoing surgery in University Hospital Limerick. Normal tissue from the 21 patients was also collected 
approximately 10 cm away from the cancer tissue. RNA was extracted from the tissue, cDNA was synthesised and real time PCR was 
carried out. All data was normalized using the housekeeping genes PRGK1, GUSB, PPIA and HRPT1. (A) Average fold change of the 
9 PKC coding genes in cancer tissue of patients compared to each patients normal tissue (n = 21). Each individual patients fold change 
was analysed using the REST© software. The table explains the corresponding PKC coding gene and PKC isoform. (B) Gene expression 
of PRKCB in normal tissue (n = 3), benign tissue (n = 2) and cancer tissue (n = 21) relative to normal distant tissue (n = 21). Data was 
analysed using the delta delta ct method (Statistical significance based on the Welch test and Bonferroni test ***p < 0.01).
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Table 1: Characteristics of the cohort of colorectal cancer (CRC) patients and summary of the 
pathology of the tumour microarrays used to analysis the expression of PKC Beta II
Stage 1 Stage 2 Stage 3 Stage 4
N 7 24 161 5
Male/Female 5\2 7\17 96\65 1\4
Age, median (range) 69 (45–75) 65 (45–86) 72 (34–94) 67 (53–92)
CRC mortality 0 8 105 4
Lymphvascular Invasion 0 2 136 0
Metastatic 0 6 24 5
Figure 2: Expression of PKC Beta II in CRC patients. PKC Beta II expression was assessed by immunohistochemistry in normal 
distant, cancer, tumor edge and normal adjacent tissue samples from CRC patients (n = 166). (A) Representative image of PKC Beta II 
staining for Normal Distant (n = 151), Cancer (n = 164), Tumor Edge (n = 119) and Normal Adjacent (n = 126) tissue. (Top panel images = 
5X, Bottom panel images = 20X). (B) Box plot representing the difference in PKC Beta II H score between normal distant, cancer, tumor 
edge and normal adjacent in epithelium (n = 151, 164, 119, 126) and stromal tissue (n = 152, 166, 121, 126) (Statistical difference based on 
Welch Test and Bonferroni test, ***p < 0.001). 
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II plays an important role in maintaining the malignant 
phenotype of HCT116 carcinoma cells as overexpression 
of PKC Beta II results in the reversal of this phenotype. 
Overexpression and activation of PKC Beta 
II reduces cell survival and IGF-1 mediated 
phosphorylation of AKT
All these results combined indicate that PKC Beta II 
is acting as a tumour suppressor in colon cancer. To gain 
an insight into the mechanistic role PKC Beta II plays, 
we examined the effect of PKC Beta II on the survival 
pathway in HCT116 cells using a number of different 
approaches. Firstly, using the xCELLigence system 
we observed that etoposide induced an increase in cell 
death in cells stably overexpressing PKC Beta II when 
compared to empty vector (p < 0.01) (Figure 5A). This 
result indicates that PKC Beta II plays a role in reducing 
the survival pathway in colon cancer cells. To investigate 
this further we examined the effect PKC activation had on 
the IGF-1 induced phosphorylation of AKT. HCT116 cells 
were treated with PMA or DMSO for 15 minutes prior 
to IGF-1 at different time intervals. Interestingly, cells 
pretreated with PMA showed a dramatic downregulation 
of IGF-1 induced phosphorylation of AKT (Figure 5B). 
This observation led us to predict that HCT116 cells 
stably overexpressing PKC Beta II would show reduced 
phosphorylated AKT compared to empty vector cells. To 
examine this we treated both groups of cells with IGF- 1, 
and observed a marked decrease in pAKT expression 
in the HCT116 cells stably overexpressing PKC Beta 
II (Figure 5C). To confirm this decrease in pAKT was 
induced by PKC activation, we next treated cells with 
the PKC inhibitor, Gö6983, five minutes prior to PMA 
treatment. As predicted, we observed that the PMA effect 
was abolished when cells were pretreated with Gö6983 
Figure 3: Disease free survival of patients with high and low expression of PKC Beta II. High and low expression of PKC 
Beta II was determined using the median H score value for normal distant tissue and cancer tissue. (A) Effect of high (n = 61) and low 
(n = 65) expression of PKC Beta II on disease free survival in the normal distant epithelium tissue of CRC patients. (B) Effect of high 
(n = 75) and low (n = 77) expression of PKC Beta II on disease free survival in the normal distant stromal tissue of CRC patients. (C) Effect 
of high (n = 22) and low (n = 126) expression of PKC Beta II on disease free survival in the cancer epithelium tissue of CRC patients. 
(D) Effect of high (n = 40) and low (n = 126) expression of PKC Beta II on disease free survival in the cancer stromal tissue of CRC 
patients. P-values represent the Log-rank test. 
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(Figure 5D, 5E). To distinguish the effect IGF- 1 and 
PMA had on PKC activity we utilized the FRET-based 
PKC reporter (CKAR), this reporter specifically uses 
changes in FRET to quantify PKC phosphorylation 
activity in real-time and in live cells. The phosphorylation-
dependent FRET ratio changes revealed that IGF-1 had 
no effect on PKC activity and the activity was specifically 
induced by PMA and inhibited by Gö6983 (Figure 5F). 
Next, using an AKT-specific FRET reporter (BKAR) 
we wanted to compare the effect of PMA treatment on 
IGF-1 induced activity of AKT. Strikingly, we observed 
that PMA treatment showed a dramatic reduction in the 
phosphorylation activity of AKT compared to untreated 
HCT116 cells (Figure 5G). The downregulation of PKC 
Beta II at both a gene and protein level in a large cohort 
of patients, combined with the reversal of the malignant 
phenotype of colon cancer cells and the dramatic effect 
it has on reducing the survival pathway in colon cancer 
cells, indicates that PKC Beta II is in fact functioning as a 
tumour suppressor. Together, these data demonstrate that 
in tumour cells, loss of PKC Beta II is an early event in 
cancer progression which leads to increased survival and 
maintenance of the transformed phenotype. 
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Figure 4: Effect of overexpression of PKC Beta II on colon cancer cells. The effect of overexpressing PKC Beta II in colon 
cancer cells was examined using HCT116 cells stably over expressing HA_PKCBeta II. (A) Representative western blot showing the 
expression of p-PKC Beta II in stable overexpressing HCT116 cells (n = 3). (B) Representative images demonstrating the difference in 
the cells ability to form colonies when overexpressing PKC Beta II (n = 3). (C) Images demonstrating the difference in the size of cells 
growing in a 3D matrix over 144 hours (n = 3). Bar graph represents the percentage difference in the size of 3D cultures at 144 hours. 
Confocal images are cells harvested and stained after 144 hours (n = 3). (D) Representative image of cells that were scored with a wound 
and allowed to migrate over 24 hours. Bar graph represents the percentage wound closer after 24 hours (n = 3). (E) Representative graph 
of cells migrating over a period of 72 hours analysed in real time on the xCELLigence system (n = 3). Bar graph represents the percentage 
difference in cell index. (F) Representative graph of cells invading over a period of 72 hours analysed in real time on the xCELLigence 
system (n = 3). Bar graph represents the percentage difference in cell index.
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DISCUSSION
Using matched normal and cancer tissue from CRC 
patients we have shown dysregulation of PKC coding 
genes in colorectal cancer patients with the most striking 
difference being a downregulation of PKC Beta II. Our 
findings also show that PKC Beta II is dramatically 
down-regulated at the protein level in the cancer tissue 
of a large cohort of CRC patients and most interestingly, 
low expression of the protein in normal distant tissue 
is associated with a reduction in disease free survival. 
Further to this, overexpression of PKC Beta II radically 
Figure 5: Effect of overexpressing and activating PKC Beta II on protection from cell death and IGF-1 mediated AKT 
phosphorylation. The effect of overexpressing PKC Beta II on protection from etoposide was examined using HCT116 cells stably 
overexpressing HA_PKCBeta II. Phorbol 12-myristate 13-acetate (PMA) was utilized to activate PKCs following which IGF-1 mediated 
AKT phosphorylation was examined. (A) Representative graph of cells proliferating following etoposide treatment at 16 hours. Data 
analysed in real time on the xCELLigence system (n = 3). Bar graph represents the percentage difference in cell index. (B) Representative 
western blot showing the effect of PMA treatment on the IGF-1 mediated expression of pAKT in HCT116 cells (n = 3). (C) Representative 
western blot indicating the difference in IGF-1 mediated phosphorylation of AKT when HCT116 cells are stably overexpressing PKC Beta 
II (n = 3). (D) Representative western blot showing the activation of PKC with the addition of PMA and the inhibition of PKC with the 
addition of Gö6983 (n = 3). (E) Representative western blot showing the effect of a PKC inhibitor on the PMA induced downregulation 
of pAKT (n = 3). (F) Normalised FRET ratio changes (mean +/− SEM) showing PKC activity from HCT116 cells co-expressing CKAR 
and RFP-tagged PKC Beta II treated with IGF-1, PMA and Gö6983. (G) Normalised FRET ratio changes (mean +/− SEM) showing AKT 
activity from HCT116 cells expressing plasma membrane targeted BKAR treated with IGF-1 and LY294002.
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decreases cell migration and invasion while also reducing 
cell survival in colon cancer cells. This study challenges 
traditional views that PKC isoforms act as tumour 
promoters, and instead demonstrates that PKC Beta II acts 
as a tumour suppressor. 
Our comprehensive gene expression analysis of all 
PKC isoforms revealed that three of the nine PKC coding 
genes (PRKCB, PRKCD and PRKCE) showed a down-
regulation greater than two in the cancer tissue, while only 
one of the genes (PRKCG) was up-regulated. It is also 
noteworthy that all other isoforms were trending towards 
down-regulation in the cancer tissue. This somewhat 
equates to a recent study which demonstrated that 61% 
of PKC mutations characterized in cancer were loss 
of function and none were activating [46], suggesting 
that suppression of PKC activity is a key part of the 
transformed phenotype. Although the gap in knowledge 
between expression at the gene and protein level needs to 
be refined, together, both these findings suggest that PKCs 
have a tumour suppressor role in colorectal cancer tissue. 
We next looked at PKC Beta II expression at the 
protein level using a large number of cancer and normal 
tissue samples obtained from CRC patients (Table 1). 
We found that there was a striking down-regulation of 
the mature protein in tissue taken from both the tumour 
itself and tissue taken from the tumour edge. Interestingly 
also, this reduction in levels of PKC Beta II was observed 
in both the epithelial and stromal tissue suggesting that 
PKC Beta II down-regulation across the entire tumour is 
an important feature of colorectal cancer. This is valuable 
information as it is becoming more apparent that the 
stromal environment is an integral part of cancer initiation 
and progression [48]. 
One of the most intriguing findings of our study 
was the strong association found between low levels of 
PKC Beta II in normal distant tissue and a reduction in 
disease free survival time for CRC patients. Again, this 
is evidence that loss of PKC activity is an important and 
early step in cell transformation. Recent meta-analysis 
conducted on clinical trials of non-small cell lung cancer 
patients given chemotherapy alone versus chemotherapy 
combined with various PKC inhibitors revealed response 
rates and disease control rates were significantly reduced 
in the groups that were administrated PKC inhibitors 
[45]. Interestingly, also, Bryostatin-1, a PKC activator 
failed in clinical trial in cervical cancer patients, however, 
this is likely to due to the effects this compound has on 
down-regulating PKCs [49–51]. As PKC inhibitors are 
not targeting cancer tissue specifically, it is likely that 
they are down-regulating PKCs globally in the patient’s 
colonic epithelium. Our findings that CRC patients that 
naturally exhibit low levels of PKC Beta II in their normal 
tissue have reduced disease free survival time, and this 
may explain why patients receiving PKC inhibitors have 
reduced disease control rates. It is not surprising that 
no relationship was found between levels of PKC Beta 
II in cancer tissue and disease free survival time, as we 
clearly found that the down-regulation of the protein is not 
enhanced by disease progression.
Considering the data, what effect might an 
increase in PKC Beta II levels have on colon cancer 
cells? In agreement with our proposed hypothesis that 
PKC Beta II inhibits tumour growth, colon cancer cells 
overexpressing the protein showed a dramatic decrease in 
the ability to form colonies in plating efficiency assays. 
The migratory and invasive capacities of these cells, as 
monitored by real-time cell analysis were also severely 
compromised. This is supported by previous work in 
which overexpressing PKC Beta II in colon cancer cells 
inhibited colony formation in soft agar and correction 
of a PKC Beta II mutation that restored activity in colon 
cancer cells reduced tumour size in nude mice [46]. 
Moreover, when we overexpressed PKC Beta II in colon 
cancer cells there was a marked reduction in the size of 
their 3-dimensional cultures and a dramatic change in 
the migratory phenotype of the cultures. Taken together, 
this demonstrates that increasing levels of PKC Beta II 
in colon cancer cells reverses the malignant phenotype of 
the cells and further points to a tumour suppressor role for 
PKC Beta II. 
What mechanistic role does PKC Beta II exhibit 
in order to suppress this cancer phenotype? A common 
advantageous hallmark of cancer cells is upregulated 
survival signalling and a resistance to cell death [52]. 
Considering that the loss of PKC Beta II appears to be an 
important early step in the formation of the transformed 
phenotype, we anticipated that PKC Beta II may play 
an important role in inhibiting the survival pathway. 
Consistent with this we found that cells overexpressing 
PKC Beta II showed a reduction in their resistance 
to cell death induced by the common cytotoxic anti-
cancer drug, etoposide. A common mechanism for the 
promotion of cell survival in cancer is through AKT 
[53]. In agreement with this we observed a marked 
downregulation of IGF- 1 mediated phosphorylation of 
AKT when PKCs were activated in colon cancer cells and 
in cells overexpressing PKC Beta II. Accordingly, this 
reduction of AKT phosphorylation was reversed when 
the cells were treated with a PKC inhibitor. We observed 
that activation of PKC by PMA was independent of IGF-1 
and IGF-1 mediated activation of AKT was significantly 
reduced in the presence of PMA. These data would 
strongly suggest that PKC Beta II plays an important 
role in suppressing the survival pathway in cancer cells 
making the downregulation of PKC Beta II an imperative 
early step in the establishment and maintainence of the 
transformed phenotype (Figure 6). 
In this study, our patient analysis combined with 
our in vivo assays provides a strong supporting argument 
that PKC Beta II functions as a tumour suppressor in the 
prevention of colorectal cancer. The study is one of the 
first suggesting this, and is supported by recent analysis 
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of cancer-associated mutations in PKC that revealed 
that all PKC mutations found in cancer are loss-of-
function [46]. This discovery together with our finding 
that a low level of PKC in normal tissue dramatically 
reduces disease free survival time would indicate that 
PKC activation does not precede its downregulation. 
By looking specifically at normal and cancer tissue 
from CRC patients, our work has strongly enhanced 
the hypothesis that PKC Beta II is acting as a tumour 
suppressor in CRC. Our findings that PKC Beta II is 
dramatically downregulated at stage one of the disease 
would suggest that loss of PKC activity is a very early 
event in the disease. This contrasts with previous work 
suggesting the up-regulation of PKC Beta II is an early 
event in colon cancer in mice [32]. These contradictory 
results reflect a recent commentary in which it was 
suggested that one of our biggest challenges in targeting 
PKCs is the limited data that are available on patient 
samples, and, the difficulties associated with translating 
animal models in the clinic [44]. Taken together; our 
findings that PKC Beta II is reduced in the stromal and 
epithelial tissue of the tumours and that low expression 
of PKC Beta II in normal tissue of CRC patients 
dramatically reduces disease free survival time, points 
strongly towards the idea that a ‘global’ down-regulation 
of PKC Beta II is an important driver of the disease. This 
provides a good explanation as to why clinical trials 
with PKC inhibitors have been largely unsuccessful and 
some in fact reduced disease control rates. Interestingly, 
very recent findings have revealed that interrupting 
K-Ras-calmodulin binding with prostratin, an orally 
active protein kinase C activator actually represses 
tumorigenesis in K-Ras driven cancers [54]. 
These data combined with our in vivo assays 
strongly highlight that PKC Beta II has an important role 
to play in the suppression of cancer. PKC Beta II may 
in fact be acting to control the activity of phosphatases 
which subsequentially regulate AKT and reduces cell 
survival (see summary Figure 6). All this evidence 
certainly challenges our current view of PKCs suggesting 
perhaps we need to reconsider how we target PKCs in 
the clinic. 
Figure 6: Model demonstrating how the absence or presence of PKC determines the rate of cell migration, invasion 
and survival. For additional information on the signals required to activate PKCs see Dowling et al (2015) [51].
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MATERIALS AND METHODS 
Clinical samples
Following ethical approval tissue samples measuring 
approximately 0.5cm in diameter were collected from 21 
patients (median age 68 y; range, 45–84; male 13, female 8) 
undergoing surgery in University Hospital Limerick. One 
patient had stage 1, 14 patients had stage 2 and 6 patients 
had stage 3 colorectal cancer. Normal tissue from the 21 
patients was also collected approximately 10 cm away from 
the cancer tissue. Specimens were immediately placed in 
Allprotect tissue reagent (Qiagen) and stored at −80oC. 
A second cohort of tissue samples was collected, 
with ethical approval, from 197 patients (median age, 71 
y; range, 34–94; male 109, female 88) undergoing surgery 
at St. James Hospital Dublin. Seven patients had stage 
1, 24 patients had stage 2, 161 patients had stage 3 and 
5 patients had stage 4 colorectal cancer. Samples were 
collected from the tumour, tumour edge, normal distant 
tissue and normal adjacent tissue. After surgery, samples 
were fixed in 10% formalin and embedded in paraffin. 
RNA extraction and cDNA synthesis 
Frozen tissue was immersed in liquid nitrogen and 
ground into powder. Lysis buffer was added to tissue and 
the sample transferred to tubes using a 21-gauge needle. 
Total RNA was extracted as per Qiagen RNeasy Mini 
Kit instructions. RNA was quantified using a Nanodrop 
Spectrophotometer (Thermo Scientific) and stored at 
−80 degrees. RNA purity was evaluated by the ratio of 
absorbance at 260/280 nm and RNA quality was evaluated 
through visualization of the 28S:18S ribosomal RNA ratio 
on a 1% agarose gel (Supplementary Figure 1A). Total 
RNA (1 μg) was synthesised into cDNA using Vilo cDNA 
synthesis kit (Invitrogen) and stored at −20 degrees. 
Real-time PCR
Real-time PCR was conducted using the ABI 
7900 HT instrument (Applied Biosystems) following 
supplier instructions. Taqman® Gene Expression Assay 
Kits (Applied Biosystems) were used to analyse the 
gene expression of the 9 coding PKCs genes. The ratio 
of stromal tissue to epithelium tissue in normal tissue 
and cancer tissue samples was analyzed using KRT18 
and VIM taqman® gene expression assays in 12 random 
tissue samples (Supplementary Figure 1B). A panel of nine 
housekeeping genes were evaluated using excel Normfinder 
and the four most stable genes were used for normalisation 
of each experiment (Supplementary Figure 1C). 
Immunohistochemistry 
Tissue microarrays (TMA) were constructed from 
formalin fixed paraffin-embedded pre-treatment tumour 
samples using 1 mm cores, and they are in triplicate 
for each patient sample. Immunohistochemistry was 
performed using a Vectastain ABC Kit (Elite), as per the 
manufacturer’s instructions. Slides were deparaffinised, 
rehydrated and heated-antigen retrieval was performed 
using Trilogy solution (Cell Marque Corporation). 
Endogenous peroxidase activity was blocked using 
hydrogen peroxide (3%) for 30 min and sections were 
blocked using goat serum and incubated with rabbit anti-
human phospho-PKC Beta II (phospho S660) (Abcam, 
1:300 dilution) for 1 h at room temperature. Sections 
were then incubated with secondary antibody for 30 min 
at room temperature. Diaminobenzidine (Sigma) was 
used to visualize staining and sections were counter-
stained with haematoxylin, dehydrated and mounted. 
Stained sections were scanned using a scanscope XT 
digital scanner and ImageScope software (Aperio 
Technologies). Expression was assessed by scoring 
positive cell count and intensity in the epithelium and 
stroma by 2 reviewers who were blinded to the TRG 
status of the patient. Positivity was assessed using 7 
categories (0%, 10%, 25%, 50%, 75%, 90% and 100%). 
Intensity was assessed using a scale of 0, 1, 2 and 3 
which correlated with negative, weak, medium and 
strong staining, respectively. The % distribution and 
intensity values were multiplied to give the ‘H score’ for 
each tissue core. 
Cell culture and stable transfection 
HCT 116 colorectal carcinoma cells were purchased 
from ATCC (ATCC® CCL-247™ with certificates of 
analysis) and were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Sigma), supplemented with 
10% (v/v) fetal calf serum, 10 mM L-Glu, and 5 mg/ml 
penicillin/streptomycin. HCT116 cells were transfected 
with pcDNA3/HA-PKC Beta II or empty pcDNA3 
vector using LipofectAMINE Plus (Invitrogen). 24 h 
after transfection HCT116 cells were split into medium 
containing G418 (1.5 mg/ml) and maintained for 14 days 
with regular replenishment of medium and drug. Cells 
were examined for the expression of HA-PKC Beta II by 
western blotting. Cells overexpressing HA-PKC Beta II 
were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 1.5 mg/ml G418. 
Colony formation assay 
Stable cell lines were harvested with trypsin/
EDTA, washed with DMEM and counted using a 
haemocytometer. 500 cells were plated per well of a 6 
well plate and incubated at 37°C in 5% CO2 for 10 days. 
Following this time, the cells were fixed in 96% ethanol 
for 10 min and subsequently stained with 0.05% crystal 
violet for 20 min. The wells were washed carefully and 
allowed to dry. Colonies were counted and recorded and a 
colony was deemed to be of 50 cells or more in size. 
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3-dimensional cell cultures 
Individual wells of a 6 well plate were coated with 
MatrigelTM (BD Biosciences) and placed in an incubator 
at 37°C for 30 min. Stable cell lines were trypsinized and 
counted. 50,000 cells/ml were resuspended in DMEM 
supplemented with 2% MatrigelTM. Cells were placed 
in MatrigelTM coated wells for 30 min at 37°C, after 
which DMEM supplemented with 2% MatrigelTM was 
added to the cultures. Cells were maintained in culture 
for 6 days in an incubator at 37°C, 5% CO2 with fresh 
medium added every 2 days and cultures imaged every 
24 hours (Olympus cellSens Dimension 1.12). On day 
6, cultures were harvested using EDTA/PBS, fixed with 
paraformaldehyde (PFA) and stained for confocal analysis 
(Zeiss LSM 710). 
Scratch wound assay 
Adhesive wound assay inserts (Ibidi) were used to 
generate wounds in confluent layers in a 6 well plate. To 
do this, stable cells were trypsinized and seeded into the 
plate to form a monolayer. After overnight growth and 
attachment, the insert was carefully removed and the cells 
were starved of serum by adding serum free media for 4 
hours, after which DMEM was added to the cells and they 
were imaged immediately (T0) using (Olympus cellSens 
Dimension 1.12). Cells were maintained in an incubator 
at 37°C, 5% CO2 for 24 hours, after which time images 
of the wound closure were taken as described above. The 
percentage wound closure was analyzed using Wimasis 
image analysis. 
Real time migration and invasion analysis
The rate of cell migration and invasion was 
monitored in real-time with the xCELLigence system 
CIM-plates. 4 hours prior to the experiment stable cell 
lines were serum starved. The upper chamber (UC) of 
the CIM-plates was coated with 1 ug/ul of fibronectin 
and for invasion experiments an additional 1:40 solution 
of MatrigelTM (BD Biosciences) was added. 30,000 cells 
were seeded in each well of the UC in serum free media. 
DMEM was added to each well of the lower chamber 
(LC). The CIM-plates was left in an incubator for 1 hour 
to allow cell attachment. The impedance value of each 
well was automatically monitored by the xCELLigence 
system (xCELLigence RTCA DP, ACEA) for duration of 
72 hours and expressed as a cell index value (CI) value. 
Real time etoposide assay 
The rate of cell death and proliferation was 
monitored in real time using the xCELLigence E-plate 
system. Either 30 000 HCT116 cells overexpressing 
PKC Beta II or 30 000 HCT116 cells expressing empty 
vector were placed in each well. The cells were allowed to 
adhere and proliferate for 16 hours following which time 
15 μM of etoposide (Sigma) was added to the cells. The 
impedance value of each well was automatically monitored 
by the xCELLigence system for 32 hours and the data was 
normalised at the point the etoposide was added. 
IGF-1 and PMA treatment of cells 
Cells were starved of serum for four hours prior 
to treatment with 50 ng of IGF-1 for the indicated times. 
The PKC inhibitor, Gö6983 (1 μM), was added 5 minutes 
prior to phorbol 12-myristate 13-acetate (PMA) and 
PMA (100 nM) was added 15 minutes prior to IGF-1. 
Cell lysates were prepared and run on 10–12% gradient 
gels and then transferred to membranes, which were 
blocked for 1 h at room temperature in TBS containing 
0.05% Tween 20 (TBS-T) and 5% milk (w/v). All 
primary antibody incubations were overnight at 4°C. 
Secondary antibody incubations were carried out at room 
temperature. 
FRET imaging and analysis 
HCT116 cells were rinsed and imaged in Hanks’ 
balanced salt solution containing 1 mM Ca2+. Images 
were acquired and analysed as previously described [55]. 
For PKC activity measurements cells were co-transfected 
with CKAR and RFP tagged rat PKC Beta II. For AKT 
activity measurements cells were transfected with plasma 
membrane targeted BKAR [56]. Cells were starved of 
serum 4 hours prior to treatment of plates with IGF-1. 
Statistical analysis 
Statistical analysis was performed using SPSS 20 
Statistical Package unless stated otherwise. Significance 
between two groups was determined by the Mann Whitney 
U Test. Significance between more than two group was 
determined by the Welch Test and differences between 
these groups were determined by the Bonferroni Test. 
Disease Free Survival was analyzed using Kalpain Meir 
survival curves and the Log Rank Test, significance is 
reflective of univariate analysis. For matched patient 
samples differences in gene expression levels was 
determined for each individual patient using Pair Wise 
Fixed Reallocation Randomisation Test© as per REST© 
software. For all statistical analysis differences were 
considered to be statistically significant at p < 0.05. 
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